Neuclone Makes Progress With Ustekinumab Trial
Australian Firm Hails Phase I Results For Stelara Rival
Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.
